A5072762948- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Immune Cell Function and Interaction
- PARP inhibition in cancer therapy
- Neutropenia and Cancer Infections
- Viral-associated cancers and disorders
- Breast Lesions and Carcinomas
- Cancer Immunotherapy and Biomarkers
- Acute Myeloid Leukemia Research
- Biosimilars and Bioanalytical Methods
- Chronic Myeloid Leukemia Treatments
- BRCA gene mutations in cancer
- T-cell and B-cell Immunology
- Colorectal Cancer Treatments and Studies
- Blood disorders and treatments
- Fungal Infections and Studies
Cardiovascular Center Bethanien
2016-2025
Praxis für Hämatologie und Onkologie
2012-2024
Goethe University Frankfurt
1998-2024
University Hospital Frankfurt
2004-2024
University of British Columbia
2024
Krankenhaus Bethanien
2009-2023
Klinikum Aschaffenburg
2016-2023
Society of Paediatric Oncology and Haematology
2002-2020
Universitäts Frauenklinik
2009-2019
Heinrich Heine University Düsseldorf
2009-2019
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic strategy. To investigate the immunogenicity human epidermal growth factor receptor 2 (HER2) –positive and triple-negative (TN) breast cancers (BCs), we evaluated tumor-infiltrating lymphocytes (TILs) immunologically relevant genes neoadjuvant GeparSixto trial. Patients Methods investigated effect adding carboplatin (Cb) to an anthracycline-plus-taxane combination (PM) on pathologic complete response...
Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations chemotherapy.From 1993 to 1998, 1201 eligible patients 15 65 years age who had newly diagnosed disease in unfavorable stage IIB or IIIA IIIB IV were randomly assigned receive eight cycles cyclophosphamide, vincristine, procarbazine, and prednisone alternating doxorubicin, bleomycin, vinblastine, dacarbazine (COPP-ABVD); etoposide, (BEACOPP); increased-dose BEACOPP, each followed...
Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer.CTCs were analyzed 2026 patients with early cancer before adjuvant chemotherapy and 1492 after using the CellSearch System. After immuno-magnetic enrichment for expressing epithelial-cell adhesion molecule, CTCs defined as nucleated cytokeratin lacking CD45. The followed a median of 35 months (range = 0-54). Kaplan-Meier analyses log-rank test used analyses. All statistical tests...
PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We prospectively investigated its given simultaneously with anthracycline-taxane-based neoadjuvant chemotherapy. PATIENTS AND METHODS Patients operable or locally advanced, HER2-positive tumors were treated preoperatively four cycles of epirubicin/cyclophosphamide followed by docetaxel without capecitabine (EC-T[X]) and trastuzumab 6 mg/kg...
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal receptor 2 (HER2)–negative metastatic breast cancer. We evaluated the efficacy, measured according to rate of pathological complete response (absence invasive and intraductal disease axillary lymph nodes), safety adding bevacizumab neoadjuvant chemotherapy early-stage
This study was aimed at detecting and characterizing circulating tumor cells (CTC) before after neoadjuvant therapy (NT) in the peripheral blood of patients with breast cancer.The clinical trial GeparQuattro incorporated NT approaches (epirubicin/cyclophosphamide prior to randomization docetaxel alone, combination capecitabine, or followed by capecitabine) additional trastuzumab treatment for HER2-positive tumors. We used Food Drug Administration-approved CellSearch system CTC detection...
Abstract Purpose: We elucidated the value of tumor-infiltrating lymphocytes (TIL) as an independent predictor for pathologic complete response (pCR) rate and a prognostic marker disease-free survival (DFS) in patients with HER2-positive breast cancer neoadjuvant setting. Experimental Design: evaluated stromal TILs 498 samples GeparQuattro (G4) GeparQuinto (G5) trials. Levels were determined continuous parameter per 10% increase lymphocyte-predominant (LPBC; ≥ 60% TILs), correlated pCR DFS....
To investigate whether combined-modality treatment (CMT) with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by extended-field radiotherapy (EF-RT) is superior to EF-RT alone in patients early favorable Hodgkin's lymphoma (HL).Between 1993 1998, 650 newly diagnosed, histology-proven HL clinical stages IA IIB without risk factors were enrolled onto this multicenter study randomly assigned receive 30 Gy plus 10 the involved field (arm A) or ABVD same B)....
PURPOSE: To explore the use of gemcitabine for treatment patients with relapsing or refractory Hodgkin’s disease. PATIENTS AND METHODS: Eligible had measurable disease and more than one previous chemotherapy regimen. Patients previously treated high-dose autologous bone marrow peripheral stem-cell support were not included. Gemcitabine, 1,250 mg/m 2 , was administered as a 30-minute intravenous infusion on days 1, 8, 15 each 28-day cycle therapy. The dosing schedule remained fixed, any dose...
Multiple myeloma (MM) is characterized by a clonal proliferation of malignant plasma cells in the bone marrow secreting monoclonal immunoglobulin (paraprotein) with specific antigenic determinants, idiotype (Id), which can be regarded as tumour‐associated antigen (TAA). In order to analyse impact dendritic cell (DC)‐based vaccine, 11 patients advanced MM were treated CD34 stem cell‐derived that pulsed Id peptides. Subsequently, received three boost immunizations every other week combination...
PURPOSE Capecitabine can be integrated either concomitantly or sequentially to anthracycline-plus-taxane-based regimens. PATIENTS AND METHODS Patients with large operable locally advanced tumors, hormone receptor-negative receptor-positive tumors but also clinically node-positive disease were recruited receive preoperatively four cycles of epirubicin plus cyclophosphamide (EC; 90 mg/m(2) and 600 mg/m(2)). then randomly assigned docetaxel (100 mg/m(2)), + capecitabine (TX; 75 1,800 (75...
PURPOSE The HD9 trial aims to evaluate whether moderate dose escalation and/or acceleration of standard polychemotherapy is beneficial for advanced-stage Hodgkin's disease (HD). Two variants a novel bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) scheme (standard escalated dose) are compared with (COPP)/doxorubicin, vinblastine, dacarbazine (ABVD). PATIENTS AND METHODS randomized, three-arm recruited patients in stages IIB IIIA risk...
Abstract Purpose: The value of Ki67 measured on residual disease after neoadjuvant chemotherapy is not sufficiently described. Experimental Design: Participants the GeparTrio study with primary breast cancer randomly received response-guided [8 cycles TAC (docetaxel/doxorubicin/cyclophosphamide) in responding and TAC-NX (vinorelbine/capecitabine) nonresponding patients] or conventional (6 TAC) according to interim response assessment. Ki-67 levels were centrally immunohistochemically...